
Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.
Staff neurologist, Unity Health Toronto–St Michael's Hospital; assistant professor, University of Toronto
Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.
Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management.
Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.
The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment.
Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.
Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.
Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.
Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.
A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.
Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.
Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.
Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.
Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.
A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.
Fred D. Lublin, MD, leads a discussion about the different classifications of secondary progressive multiple sclerosis, including the relationship between disease activity and progression of disease.
An overview of the criteria used to diagnose relapsing-remitting multiple sclerosis when it converts to secondary progressive multiple sclerosis.
A panel of experts led by Bruce Cree, MD, highlight the clinical subtypes of multiple sclerosis including presentation and prevalence.
Published: April 29th 2021 | Updated:
Published: April 1st 2021 | Updated:
Published: April 8th 2021 | Updated:
Published: April 1st 2021 | Updated:
Published: May 6th 2021 | Updated:
Published: March 18th 2021 | Updated: